Pharmacokinetics of deramciclane in rabbits

József Lengyel, Erzsébet Bojti, Andrea Bolehovszky, Gyula Grézal, I. Klebovich, K. Magyar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The pharmacokinetics of deramciclane (CAS 120444-78-8, EGIS-3886) was investigated in rabbits after i.v., p.o. and s.c. administration of 3 mg/kg 14C-phenyl-deramciclane. The plasma concentration-time curves of total radioactivity, the parent compound (deramciclane) and its N-demethylated metabolite (EGIS-7056) were determined. The radioactivity level was measured by liquid scintillation technique while the concentration of the parent compound and its metabolite was determined by gas chromatography-mass spectrometry detection. The p.o. and i.v. studies were carried out on the same group of animals, while a separate group of rabbits was used for studying s.c. absorption. Deramciclane was readily absorbed after p.o. and s.c. treatment (t(max) 1.0 to 1.4 h). The terminal elimination half-life (t( 1/2 /β)) of the parent compound fell between 5.8 to 7.1 h, while that of the total radioactivity ranged from 21.6 and 26.0 h. The absolute bioavailability of deramciclane calculated from the AUC(0-∞) values was found to be 43 and 60% after p.o. and s.c. treatment. The apparent volume of distribution (V(d)) and the whole body clearance (Cl) of deramciclane after i.v. administration were 25.0 ± 7.1 l/kg and 2.6 ± 0.5 l/h/kg, respectively. The AUC(0-∞) values of the parent compound varied between 4.6 and 7.9% of that of total radioactivity, suggesting that deramciclane was subjected to intensive metabolic conversion. The AUC(0-∞) of N-desmethyl- deramciclane was 5.7%, compared to that of the parent compound after i.v. administration.

Original languageEnglish
Pages (from-to)1063-6068
Number of pages5006
JournalArzneimittel-Forschung
Volume48
Issue number11
Publication statusPublished - 1998

Fingerprint

Pharmacokinetics
Rabbits
Radioactivity
Area Under Curve
Metabolites
deramciclane
Scintillation
Gas chromatography
Gas Chromatography-Mass Spectrometry
Biological Availability
Mass spectrometry
Half-Life
Animals
Plasmas
Liquids

Keywords

  • C-Deramciclane, pharmacokinetics, rabbit
  • Anxiolytic drug
  • CAS 120444-78-8
  • EGIS-3886

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Pharmacology

Cite this

Lengyel, J., Bojti, E., Bolehovszky, A., Grézal, G., Klebovich, I., & Magyar, K. (1998). Pharmacokinetics of deramciclane in rabbits. Arzneimittel-Forschung, 48(11), 1063-6068.

Pharmacokinetics of deramciclane in rabbits. / Lengyel, József; Bojti, Erzsébet; Bolehovszky, Andrea; Grézal, Gyula; Klebovich, I.; Magyar, K.

In: Arzneimittel-Forschung, Vol. 48, No. 11, 1998, p. 1063-6068.

Research output: Contribution to journalArticle

Lengyel, J, Bojti, E, Bolehovszky, A, Grézal, G, Klebovich, I & Magyar, K 1998, 'Pharmacokinetics of deramciclane in rabbits', Arzneimittel-Forschung, vol. 48, no. 11, pp. 1063-6068.
Lengyel J, Bojti E, Bolehovszky A, Grézal G, Klebovich I, Magyar K. Pharmacokinetics of deramciclane in rabbits. Arzneimittel-Forschung. 1998;48(11):1063-6068.
Lengyel, József ; Bojti, Erzsébet ; Bolehovszky, Andrea ; Grézal, Gyula ; Klebovich, I. ; Magyar, K. / Pharmacokinetics of deramciclane in rabbits. In: Arzneimittel-Forschung. 1998 ; Vol. 48, No. 11. pp. 1063-6068.
@article{32a091d3343a4f3385ebf204b802bd4f,
title = "Pharmacokinetics of deramciclane in rabbits",
abstract = "The pharmacokinetics of deramciclane (CAS 120444-78-8, EGIS-3886) was investigated in rabbits after i.v., p.o. and s.c. administration of 3 mg/kg 14C-phenyl-deramciclane. The plasma concentration-time curves of total radioactivity, the parent compound (deramciclane) and its N-demethylated metabolite (EGIS-7056) were determined. The radioactivity level was measured by liquid scintillation technique while the concentration of the parent compound and its metabolite was determined by gas chromatography-mass spectrometry detection. The p.o. and i.v. studies were carried out on the same group of animals, while a separate group of rabbits was used for studying s.c. absorption. Deramciclane was readily absorbed after p.o. and s.c. treatment (t(max) 1.0 to 1.4 h). The terminal elimination half-life (t( 1/2 /β)) of the parent compound fell between 5.8 to 7.1 h, while that of the total radioactivity ranged from 21.6 and 26.0 h. The absolute bioavailability of deramciclane calculated from the AUC(0-∞) values was found to be 43 and 60{\%} after p.o. and s.c. treatment. The apparent volume of distribution (V(d)) and the whole body clearance (Cl) of deramciclane after i.v. administration were 25.0 ± 7.1 l/kg and 2.6 ± 0.5 l/h/kg, respectively. The AUC(0-∞) values of the parent compound varied between 4.6 and 7.9{\%} of that of total radioactivity, suggesting that deramciclane was subjected to intensive metabolic conversion. The AUC(0-∞) of N-desmethyl- deramciclane was 5.7{\%}, compared to that of the parent compound after i.v. administration.",
keywords = "C-Deramciclane, pharmacokinetics, rabbit, Anxiolytic drug, CAS 120444-78-8, EGIS-3886",
author = "J{\'o}zsef Lengyel and Erzs{\'e}bet Bojti and Andrea Bolehovszky and Gyula Gr{\'e}zal and I. Klebovich and K. Magyar",
year = "1998",
language = "English",
volume = "48",
pages = "1063--6068",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetics of deramciclane in rabbits

AU - Lengyel, József

AU - Bojti, Erzsébet

AU - Bolehovszky, Andrea

AU - Grézal, Gyula

AU - Klebovich, I.

AU - Magyar, K.

PY - 1998

Y1 - 1998

N2 - The pharmacokinetics of deramciclane (CAS 120444-78-8, EGIS-3886) was investigated in rabbits after i.v., p.o. and s.c. administration of 3 mg/kg 14C-phenyl-deramciclane. The plasma concentration-time curves of total radioactivity, the parent compound (deramciclane) and its N-demethylated metabolite (EGIS-7056) were determined. The radioactivity level was measured by liquid scintillation technique while the concentration of the parent compound and its metabolite was determined by gas chromatography-mass spectrometry detection. The p.o. and i.v. studies were carried out on the same group of animals, while a separate group of rabbits was used for studying s.c. absorption. Deramciclane was readily absorbed after p.o. and s.c. treatment (t(max) 1.0 to 1.4 h). The terminal elimination half-life (t( 1/2 /β)) of the parent compound fell between 5.8 to 7.1 h, while that of the total radioactivity ranged from 21.6 and 26.0 h. The absolute bioavailability of deramciclane calculated from the AUC(0-∞) values was found to be 43 and 60% after p.o. and s.c. treatment. The apparent volume of distribution (V(d)) and the whole body clearance (Cl) of deramciclane after i.v. administration were 25.0 ± 7.1 l/kg and 2.6 ± 0.5 l/h/kg, respectively. The AUC(0-∞) values of the parent compound varied between 4.6 and 7.9% of that of total radioactivity, suggesting that deramciclane was subjected to intensive metabolic conversion. The AUC(0-∞) of N-desmethyl- deramciclane was 5.7%, compared to that of the parent compound after i.v. administration.

AB - The pharmacokinetics of deramciclane (CAS 120444-78-8, EGIS-3886) was investigated in rabbits after i.v., p.o. and s.c. administration of 3 mg/kg 14C-phenyl-deramciclane. The plasma concentration-time curves of total radioactivity, the parent compound (deramciclane) and its N-demethylated metabolite (EGIS-7056) were determined. The radioactivity level was measured by liquid scintillation technique while the concentration of the parent compound and its metabolite was determined by gas chromatography-mass spectrometry detection. The p.o. and i.v. studies were carried out on the same group of animals, while a separate group of rabbits was used for studying s.c. absorption. Deramciclane was readily absorbed after p.o. and s.c. treatment (t(max) 1.0 to 1.4 h). The terminal elimination half-life (t( 1/2 /β)) of the parent compound fell between 5.8 to 7.1 h, while that of the total radioactivity ranged from 21.6 and 26.0 h. The absolute bioavailability of deramciclane calculated from the AUC(0-∞) values was found to be 43 and 60% after p.o. and s.c. treatment. The apparent volume of distribution (V(d)) and the whole body clearance (Cl) of deramciclane after i.v. administration were 25.0 ± 7.1 l/kg and 2.6 ± 0.5 l/h/kg, respectively. The AUC(0-∞) values of the parent compound varied between 4.6 and 7.9% of that of total radioactivity, suggesting that deramciclane was subjected to intensive metabolic conversion. The AUC(0-∞) of N-desmethyl- deramciclane was 5.7%, compared to that of the parent compound after i.v. administration.

KW - C-Deramciclane, pharmacokinetics, rabbit

KW - Anxiolytic drug

KW - CAS 120444-78-8

KW - EGIS-3886

UR - http://www.scopus.com/inward/record.url?scp=0031788201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031788201&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 1063

EP - 6068

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 11

ER -